Eleison’s mission is to acquire, develop, and commercialize clinical stage drug candidates for “orphan” cancers, providing new hope for patients with rare, life-threatening diseases.

ABOUT ELEISON’S CLINICAL TRIALS

Clinical trials are an important and necessary component of the drug development process, in order to evaluate the safety and efficacy of new drug candidates. Eleison is currently conducting clinical trials of its two drug candidates at leading hospitals and cancer treatment centers in the United States and around the world. Read More…

Eleison is currently developing ILC, a breakthrough therapeutic for the treatment of patients with a rare form of bone cancer known as osteosarcoma .

INHALED LIPID-COMPLEXED CISPLATIN - “ILC”● Engineered specifically for nebulized lung delivery.● Patented lipid formulation of cisplatin in ~0.4 μm particles deliver sustained

drug release in the lung. ● Concentrations in lung at least 10x higher and systemic toxicities much lower

than intravenous dosing of cisplatin.

● Safety data showed no hematologic toxicity, nephrotoxicity, ototoxicity, or neurotoxicity.

ILC has been tested in dozens of patients in several clinical trials.

ILC clinical trial activity:

● ILC has been tested in patients with NSCLC (non-small cell lung cancer), bronchoalveolar cancer, and osteosarcoma.

● ILC is currently being evaluated in a phase II clinical trial, to test the safety and efficacy of ILC in patients with osteosarcoma which has spread to the lungs.

● Participating hospitals in the ongoing clinical trial for osteosarcoma include Memorial Sloan-Kettering, Montefiore Children’s Hospital, Moffitt Cancer Center, University of Chicago Children’s Hospital, Children’s Hospital of Los Angeles, University of Utah Primary Children’s Hospital, Washington University (St. Louis), and others soon to be added. See www.clinicaltrials.gov for more information about Eleison’s clinical trial of ILC.

Osteosarcoma is a rare and often fatal bone cancer.

About Osteosarcoma:

● Osteosarcoma is primarily a disease of teenagers and young adults. ● 500 new cases annually in US, 800 new cases annually in Europe. ● Upon diagnosis, patients are treated with surgery and systemic combination

chemotherapy. ● 30% to 35% of patients fail first-line therapy, most commonly with

metastatic recurrence only in the lungs, with poor prognosis (five year survival of such patients is < 25%)

● No drugs are currently approved in the U.S. to treat osteosarcoma patients who have failed first-line therapy.

For More Information:

Eleison Pharmaceuticals, LLC

263 13th Avenue South, Suite 375St. Petersburg, FL 33701

ph: 215-554-3530info@eleison-pharma.com